AI Generated
Jun 28, 2026, 09:55
Utkarsh Pandey: Japan Approves Wayrilz for ITP Patients
Utkarsh Pandey, Principal Study Data Manager Leader at Sanofi, shared a post on LinkedIn:
“Exciting news!
Wayrilz (rilzabrutinib) has received approval in Japan for the treatment of immune thrombocytopenia (ITP).
This approval is supported by the LUNA 3 phase 3 study, which demonstrated rapid and durable platelet response. It is a significant milestone for patients managing this rare, complex immune disease.”
Stay updated with Hemostasis Today.
-
Sep 22, 2026, 19:02Blocking Histone-Induced Platelet-Erythrocyte Interactions With Polyanions – Platelets Journal
-
Sep 22, 2026, 18:49Abdul Rahman Hamad: Early Action for Better Outcomes in Deep Vein Thrombosis
-
Sep 22, 2026, 18:37Carmine Siniscalchi: Age-Adjusted D-Dimer Cutoffs in DVT Diagnosis
-
Sep 22, 2026, 18:37Stefano Romeo: The Cardiovascular Patient Journey is Still Full of Gaps
-
Sep 22, 2026, 18:11Bharath Kumar V.։ Advancing Safer Anticoagulation for Cancer-Associated Thrombosis
-
Sep 22, 2026, 18:10Fatima Zahra: ASH Released New Guidelines on the Diagnosis of Iron Deficiency
-
Sep 22, 2026, 17:49Nirav Dhanesha: Targeting FXI for Safer Anticoagulation
-
Sep 22, 2026, 17:17Eric Lambert: Intravascular Imaging and the Future of Precision PCI
-
Sep 22, 2026, 16:45Claudiu Stoicescu: Are We Starting Cardiovascular Risk Assessment Too Late?